| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Torino C et al. | Vitamin D and methylarginines in chronic kidney disease (CKD). | 2017 | PLoS ONE | pmid:28976989 |
| Chung S et al. | Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. | 2017 | PLoS ONE | pmid:28753620 |
| Xun J et al. | JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity. | 2017 | Oncotarget | pmid:28423536 |
| Poveda J et al. | MXRA5 is a TGF-β1-regulated human protein with anti-inflammatory and anti-fibrotic properties. | 2017 | J. Cell. Mol. Med. | pmid:27599751 |
| Zheng JQ et al. | Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. | 2016 | Nutrients | pmid:27827962 |
| Manjarres L et al. | Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. | 2016 | BMC Health Serv Res | pmid:27566059 |
| Nieuwland AJ et al. | Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm. | 2016 | Lab. Invest. | pmid:27239732 |
| El-Shemi AG et al. | Paricalcitol Enhances the Chemopreventive Efficacy of 5-Fluorouracil on an Intermediate-Term Model of Azoxymethane-Induced Colorectal Tumors in Rats. | 2016 | Cancer Prev Res (Phila) | pmid:27020656 |
| Lee AS et al. | Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway. | 2016 | Int. J. Mol. Med. | pmid:26954764 |
| Egido J et al. | The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism. | 2016 | Nefrologia | pmid:26705959 |
| Martinez-Moreno JM et al. | Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. | 2016 | FASEB J. | pmid:26700731 |
| Riera M et al. | Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. | 2016 | Am. J. Physiol. Renal Physiol. | pmid:26697977 |
| Becs G et al. | Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells. | 2016 | J. Cell. Mol. Med. | pmid:26499096 |
| Stavenuiter AW et al. | Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis. | 2015 | Biomed Res Int | pmid:26605330 |
| Borrego Utiel FJ et al. | Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. | 2015 | Nefrologia | pmid:26306956 |
| Dauletbaev N et al. | Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1. | 2015 | Br. J. Pharmacol. | pmid:26178144 |
| Zerr P et al. | Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. | 2015 | Ann. Rheum. Dis. | pmid:24448349 |
| Brakta S et al. | Role of vitamin D in uterine fibroid biology. | 2015 | Fertil. Steril. | pmid:26079694 |
| Morgado-Pascual JL et al. | Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. | 2015 | Biomed Res Int | pmid:26064952 |
| Dáňová K et al. | NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. | 2015 | Oncotarget | pmid:26053099 |
| Stavenuiter AW et al. | A novel rat model of vitamin D deficiency: safe and rapid induction of vitamin D and calcitriol deficiency without hyperparathyroidism. | 2015 | Biomed Res Int | pmid:25815325 |
| Riccio E et al. | Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. | 2015 | PLoS ONE | pmid:25781618 |
| Ritter CS et al. | Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats. | 2015 | Kidney Int. | pmid:25692955 |
| Thethi TK et al. | Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. | 2015 | J. Diabetes Complicat. | pmid:25633573 |
| Bover J et al. | Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. | 2015 | Nefrologia | pmid:25611831 |
| Kröpelin TF et al. | Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. | 2015 | Clin J Am Soc Nephrol | pmid:25568217 |
| Trillini M et al. | Paricalcitol for secondary hyperparathyroidism in renal transplantation. | 2015 | J. Am. Soc. Nephrol. | pmid:25194004 |
| Cozzolino M et al. | Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. | 2014 | Nephrol. Dial. Transplant. | pmid:24500308 |
| Wang AY et al. | Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. | 2014 | J. Am. Soc. Nephrol. | pmid:24052631 |
| Sharma A et al. | Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. | 2014 | Clin Drug Investig | pmid:24214232 |
| Donate-Correa J et al. | Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. | 2014 | Mediators Inflamm. | pmid:24511210 |
| Eren Z et al. | Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. | 2014 | Kidney Blood Press. Res. | pmid:25532067 |
| Duffy MM et al. | Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney. | 2014 | Am. J. Physiol. Renal Physiol. | pmid:25339699 |
| Sahin I et al. | Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model. | 2014 | Eur Rev Med Pharmacol Sci | pmid:25339484 |
| Ritter C et al. | Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats. | 2014 | Kidney Blood Press. Res. | pmid:25300759 |
| González-Mateo GT et al. | Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. | 2014 | PLoS ONE | pmid:25279459 |
| Choudhury S et al. | Abnormal calcium handling and exaggerated cardiac dysfunction in mice with defective vitamin d signaling. | 2014 | PLoS ONE | pmid:25268137 |
| Zoccali C et al. | Paricalcitol and endothelial function in chronic kidney disease trial. | 2014 | Hypertension | pmid:25259743 |
| Hansen D et al. | The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study. | 2014 | BMC Nephrol | pmid:25112372 |
| Suarez-Martinez E et al. | Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice. | 2014 | Ther Adv Cardiovasc Dis | pmid:25037058 |
| Carpenter TO et al. | Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. | 2014 | J. Clin. Endocrinol. Metab. | pmid:25029424 |
| Coyne DW et al. | A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. | 2014 | Clin J Am Soc Nephrol | pmid:24970869 |
| Halder SK et al. | Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. | 2014 | Reprod Sci | pmid:24925855 |
| Manucha W | [Mitochondria and oxidative stress participation in renal inflammatory process]. | 2014 | Medicina (B Aires) | pmid:24918679 |
| Lee JW et al. | Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-κB pathway in ischemia/reperfusion-induced acute kidney injury. | 2014 | Biochem. Biophys. Res. Commun. | pmid:24434153 |
| Sezer S et al. | Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients. | 2014 | Int J Artif Organs | pmid:24619898 |
| Ellam T et al. | Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. | 2014 | PLoS ONE | pmid:24586387 |
| GarcÃa IM et al. | Vitamin D receptor-modulated Hsp70/AT1 expression may protect the kidneys of SHRs at the structural and functional levels. | 2014 | Cell Stress Chaperones | pmid:24222043 |
| Freundlich M et al. | Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. | 2014 | Am. J. Hypertens. | pmid:24072555 |
| Gueutin V et al. | [Diabetic nephropathy: emerging treatments]. | 2014 | Nephrol. Ther. | pmid:24938412 |
| Rubel D et al. | Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. | 2014 | Nephrol. Dial. Transplant. | pmid:24198271 |
| Pauwels S et al. | Minimal interference from paricalcitol (Zemplar®) in underivatized 1,25-dihydroxyvitamin D LC-MS/MS assays. | 2014 | Clin. Chim. Acta | pmid:24326126 |
| Guo C et al. | Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. | 2014 | Mol Nutr Food Res | pmid:24039193 |
| Yan Y et al. | Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects. | 2014 | Clin. Nephrol. | pmid:24131674 |
| Chen S and Gardner DG | Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. | 2013 | J. Steroid Biochem. Mol. Biol. | pmid:22989481 |
| El-Khoury JM et al. | Does Paricalcitol (Zemplar®) interfere with 1,25-dihydroxyvitamin D measurement by liquid chromatography-tandem mass spectrometry assays? | 2013 | Clin. Chim. Acta | pmid:23142648 |
| Pérez V et al. | Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients. | 2013 | Eur. J. Pharmacol. | pmid:23567070 |
| Gonzalez E et al. | Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. | 2013 | Transplantation | pmid:23545517 |
| Moe SM and Thadhani R | What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? | 2013 | Curr. Opin. Nephrol. Hypertens. | pmid:24100218 |
| Sharma A et al. | Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. | 2013 | J Med Econ | pmid:23834479 |
| Havakuk O et al. | Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model. | 2013 | Isr. Med. Assoc. J. | pmid:24511650 |
| Hojs N et al. | Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients. | 2013 | Ther Apher Dial | pmid:23931873 |
| de Boer IH et al. | Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. | 2013 | Kidney Int. | pmid:22913981 |
| Azak A et al. | Effect of novel vitamin D receptor activator paricalcitol on renal ischaemia/reperfusion injury in rats. | 2013 | Ann R Coll Surg Engl | pmid:24112495 |
| Chen B et al. | Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects. | 2013 | Bioorg. Med. Chem. Lett. | pmid:24035340 |
| Larsen T et al. | Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. | 2013 | BMC Nephrol | pmid:23889806 |
| Nigwekar SU and Thadhani RI | Shining light on vitamin D trials in chronic kidney disease. | 2013 | Kidney Int. | pmid:23364588 |
| Atchison DK et al. | Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity. | 2013 | Am. J. Physiol. Renal Physiol. | pmid:23926179 |
| Amer H et al. | Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. | 2013 | Am. J. Transplant. | pmid:23601186 |
| Bae S et al. | Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction. | 2013 | J. Appl. Physiol. | pmid:23429874 |
| Duplancic D et al. | The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. | 2013 | Clin Interv Aging | pmid:23430986 |
| Sánchez-Ãlvarez JE et al. | Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. | 2013 | Nefrologia | pmid:23364628 |
| Piñera-Haces C et al. | Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. | 2013 | Nefrologia | pmid:23364629 |
| Dyer CA | Safety and tolerability of paricalcitol in patients with chronic kidney disease. | 2013 | Expert Opin Drug Saf | pmid:23621417 |
| Axelsson J et al. | Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. | 2013 | Am. J. Physiol. Renal Physiol. | pmid:23657856 |
| Verouti SN et al. | Paricalcitol effects on activities and metabolism of platelet activating factor and on inflammatory cytokines in hemodialysis patients. | 2013 | Int J Artif Organs | pmid:23335378 |
| Pérez-Gómez MV et al. | Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. | 2013 | Nefrologia | pmid:24089164 |
| de Lorenzo A et al. | Oral paricalcitol as antiproteinuric agent in chronic kidney disease. | 2013 | Nefrologia | pmid:24089163 |
| del Pozo-Fernández C et al. | Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term. | 2013 | Nefrologia | pmid:24089159 |
| Lawrence JA et al. | Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. | 2013 | Cancer Biol. Ther. | pmid:23760489 |
| Panizo S et al. | Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. | 2013 | Nephrol. Dial. Transplant. | pmid:24013683 |
| Navarro-González JF et al. | Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. | 2013 | J Clin Pharmacol | pmid:23426718 |
| Bellasi A et al. | Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. | 2013 | Blood Purif. | pmid:23736115 |
| Wu-Wong JR et al. | Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. | 2013 | Life Sci. | pmid:23261531 |
| Han T et al. | Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. | 2013 | Biomed Res Int | pmid:23509710 |
| Pacini S et al. | Effects of vitamin D3 and paricalcitol on immature cardiomyocytes: a novel role for vitamin D analogs in the prevention of cardiovascular diseases. | 2013 | Nutrients | pmid:23749205 |
| Hwang HS et al. | Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. | 2013 | Nephrol. Dial. Transplant. | pmid:23229926 |
| Ramos R et al. | Effectiveness of treatment with oral paricalcitol in patients on peritoneal dialysis: a Spanish multicenter study. | 2013 | Clin. Nephrol. | pmid:23320973 |
| Coyne DW et al. | Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. | 2013 | Nephrol. Dial. Transplant. | pmid:23787544 |
| Kim CS et al. | Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. | 2013 | PLoS ONE | pmid:23690997 |
| Ong LM et al. | Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. | 2013 | Nephrology (Carlton) | pmid:23311404 |
| De Nicola L et al. | Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. | 2012 | BMC Nephrol | pmid:23167771 |
| Pohjolainen V et al. | Left ventricular periostin gene expression is associated with fibrogenesis in experimental renal insufficiency. | 2012 | Nephrol. Dial. Transplant. | pmid:21712488 |
| Noertersheuser PA et al. | Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. | 2012 | J Clin Pharmacol | pmid:21940716 |
| Kovesdy CP et al. | Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. | 2012 | Am. J. Kidney Dis. | pmid:21885174 |
| Komaba H and Fukagawa M | Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification? | 2012 | Kidney Int. | pmid:23203019 |
| Kant KS et al. | Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol. | 2012 | J Ren Nutr | pmid:21652220 |
| Verouti SN et al. | Vitamin D receptor activators upregulate and rescue podocalyxin expression in high glucose-treated human podocytes. | 2012 | Nephron Exp. Nephrol. | pmid:23548800 |
| Miller JE et al. | Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. | 2012 | Pharmacoepidemiol Drug Saf | pmid:22996597 |
| Izquierdo MJ et al. | Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. | 2012 | BMC Nephrol | pmid:23186077 |
Paricalcitol
Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.
Cross Reference
Introduction
To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Paricalcitol?
Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with Paricalcitol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Paricalcitol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Paricalcitol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What genes are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What common seen animal models are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.